Phase 4
Completed N=65
Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression
Source: ClinicalTrials.gov NCT01479829 ↗Enrolled (actual)
65
Serious AEs
0.0%
Results posted
Apr 2024
Primary outcomePrimary: Response to Treatment — 21; 9; 6; 11 Participants — p=.02
◆ Published Evidence
Established
57citations · ~10 / year
Modulation of the inflammatory response benefits treatment-resistant bipolar depression: A randomized clinical trial.
Summary
This project will attempt to enhance and augment the antidepressant efficacy of a commonly used antidepressant in poorly responding bipolar depressed patients.
Linked Publications (2)
-
Modulation of the inflammatory response benefits treatment-resistant bipolar depression: A randomized clinical trial.
-
Effects of adjunctive inflammatory modulation on IL-1β in treatment resistant bipolar depression.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Response to Treatment |
21; 9; 6; 11 | .02 sig |
| PRIMARY Disease Remission |
17; 2; 10; 18 | <.001 sig |
Eligibility Criteria
Inclusion Criteria
- Ages 21 - 65 years old at time of screening visit. Both genders and any race will be accepted.
- Diagnosis of BPD I or II without significant co-morbid secondary medical or psychiatric diagnoses; no substance abuse or dependence during preceding 12 months
- A minimum score of 18 on the first 17 items of the 21-item Hamilton Depression Scale
- Willingness to washout for a reasonable time (depending on the substance) from: Vitamin E and fish oils (>600 IU/day), non-aspirin NSAIDs or aspirin (>81 mg/day, H2 receptor antagonists, Ginko biloba, caffeine on morning of blood drawing, and to institute lights-out at 23:00 hours on the nights before blood drawings
Exclusion Criteria
- Any abnormal findings on the physical exam, ECG, blood/urine or minor infections
- Any pre-existing physical pain condition, including fibromyalgia
- History of peptic ulcer complicated by perforation, hemorrhage, or obstruction; symptoms of peptic ulcer within 4 weeks of enrollment date
- Any substance abuse or dependence during the preceding 12 months
- Clinically significant hypertension, anemia, liver disease, kidney disease, arthritis, diabetes, recurrent migraines, epilepsy, stroke, gum disease, autoimmune disease
- Current use of lithium
- Current use of a stimulant
- Certain steroids including use of hormonal birth control and any systemic or topical corticosteroids (hormone replacement therapy will be allowed)
- Unwillingness to refrain from H2 receptor antagonists, non-aspirin NSAIDs, or aspirin (more than 1 mg/day).
- Use of any anticoagulant agents
- Use of nicotine-containing substances. Subjects who quit smoking more than 3 months prior to assessment may be considered for the study
- Known sensitivity or allergy to the study medications or a need to receive agents that are contra-indicated in combination with CBX or ESC
- Unwillingness to fast and abstain from caffeine on mornings of blood drawings
- A sleep disorder other than insomnia or hypersomnia as a distinct symptom of major depressive disorder (MDD)
- Inability to commit to the follow-up visits between 8 and 11 am
Data sourced from ClinicalTrials.gov (NCT01479829) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.